Baylis Medical Company Inc. will be acquired by Boston Scientific
Baylis Medical Company Inc. has agreed to be acquired by Boston Scientific Corporation for a $1.75 billion upfront payment, subject to closing adjustments.
As part of this acquisition, Boston Scientific will have access to radiofrequency platforms NRG® and VersaCross® Transseptal, along with items such as sheaths, guidewires and dilators that are designed to support left heart access.
The transseptal protocols of these platforms enable surgeons to increase safety, efficacy and efficiency when they cross the atrial septum to carry out therapies on the left side of the heart, including operations like atrial fibrillation ablation and LAAC closure, as well as processes like mitral valve interventions.
After achieving year-over-year sales growth in the double digits each of its past five years, Baylis Medical Company is expected to generate revenues approaching $200 million by 2022.
Mike Mahoney, the chief executive officer and chairman of Boston Scientific, commented:
“The talented and innovative Baylis Medical Company team, combined with these transseptal platforms, will enhance our efforts to improve procedural efficiencies with physician tools designed to make left atrial access safer and more predictable, with a focus on patient outcomes. A leader in many of the fastest growing markets in our industry, we believe that Baylis Medical Company will add meaningful revenue, operating income, and new research and development capabilities across multiple Boston Scientific businesses, while complementing existing offerings within our electrophysiology and structural heart portfolios.”
Medical professionals have traditionally injected medicine into the left side of the heart using a mechanical needle that passes through the septum. This can present safety concerns and placement challenges, depending on the patient’s anatomy.
Instead of depending on mechanical force alone, Baylis Medical Company platforms use RF energy in order to achieve safe and predictable transseptal access. This method increases efficiency, improving the safety and efficacy of transseptal puncture while left heart procedures take place.
Using VersaCross, therapeutic delivery of transseptal crossing procedures can be further optimized. By eliminating potential wire and sheath exchanges, the VersaCross platform may help mitigate risk during procedures.
A 510(k) clearance was granted by the Food and Drug Administration (FDA) for Baylis Medical Company’s NRG platform in 2008, and since then has been used in more than one million procedures.
© Baylis Medical
© Boston Scientific Corporation